Moderna Inc. ($MRNA) Stock Forecast: Down 6.1% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company renowned for its mRNA technology, notably in the field of vaccine development, such as the COVID-19 vaccine.

Why is Moderna Inc. going down?

MRNA stock is down 6.1% on May 7, 2026 20:00

• The stock of Moderna faced a downward trend today despite the positive developments related to its mRNA technology and vaccine progress.
• Following the release of robust Q1 outcomes and promising data on its COVID vaccine, Novavax's stock saw a significant increase, potentially shifting investor focus away from Moderna.
• Concerns arose within the biotech sector after the Phase 3 trial failure of Lipocine's LPCN 1154 for postpartum depression, impacting Moderna's stock.
• Internal disagreements at the FDA, exemplified by Sanofi requesting the removal of Tzield from the CNPV program, might have instigated uncertainty over regulatory procedures for companies like Moderna, influencing the downward movement.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna Stock Rallied on Hantavirus Fears. What to Know.

Moderna's stock briefly surged on Thursday after news emerged about a cluster of hantavirus cases. These cases originated from passengers on a cruise ship traveling from Argentina to Cabo Verde. The World Health Organization has deemed the public health risk as low.

https://www.barrons.com/articles/moderna-stock-rallied-on-hantavirus-fears-what-to-know-190df56c

PPD drug LPCN 1154 misses endpoint as Lipocine (NASDAQ: LPCN) posts Q1 loss

Lipocine (NASDAQ: LPCN) announced that its Phase 3 trial for LPCN 1154, an oral brexanolone for postpartum depression, did not meet its primary endpoint, failing to show a statistically significant improvement in HAM-D scores. Despite this, a post hoc analysis revealed statistically significant benefits in participants with a history of psychiatric conditions, leading Lipocine to apply for breakthrough therapy and fast track designations. The company also reported a wider net loss of $3.7 million in Q1 2026, primarily due to increased research and development spending on LPCN 1154, though its cash and investment balances increased.

https://www.stocktitan.net/sec-filings/LPCN/8-k-lipocine-inc-reports-material-event-10342b3f91bd.html

Sanofi requests removal of Tzield from CNPV program after Høeg gets involved

Sanofi has reportedly asked the FDA to remove its type 1 diabetes drug, Tzield, from the Commissioner’s National Priority Review program due to a disagreement with acting CDER Director Tracy Beth Høeg, who expressed concerns about the drug's risks. This follows FDA staff's recommendation to expand Tzield's label, a decision Høeg opposed. The situation highlights ongoing tensions within the FDA regarding political appointees influencing drug approval processes, with other recent cases involving Replimune's melanoma drug and Moderna's flu vaccine.

https://www.biospace.com/fda/sanofi-requests-removal-of-tzield-from-cnpv-program-after-h%C3%B8eg-gets-involved

NVAX Stock Eyes Breakout Week: Novavax Claims Patients Were ‘Twice As Likely’ To Pick Its COVID Shot Over Moderna Again

Novavax (NVAX) shares are experiencing a breakout week after the company reported strong Q1 results, surpassing analyst estimates with revenue of $139.5 million. The positive performance was further bolstered by new data indicating that Novavax's Nuvaxovid COVID vaccine produced "statistically fewer side effects" than Moderna's mNEXSPIKE, leading patients to be "twice as likely" to choose it again. Novavax also reaffirmed its 2026 adjusted revenue outlook and highlighted licensing agreements with Pfizer and Sanofi, which are expected to generate significant milestone and royalty revenues as the company shifts its focus from direct vaccine sales.

https://stocktwits.com/news-articles/markets/equity/nvax-stock-breakout-week-covid-shot-over-moderna-again/cZXb2xNRef1

MRNA SEC Filings - Moderna 10-K, 10-Q, 8-K Forms

This page on Stock Titan provides comprehensive access to Moderna (MRNA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. It aims to offer investors detailed insights into the company's financial condition, governance, and pipeline priorities. The platform enhances this information by organizing filings chronologically, by type, and offers AI-powered summaries to quickly highlight main points from lengthy documents.

https://www.stocktitan.net/sec-filings/MRNA/page-7.html

Trending Today

Heating Oil ($HEATOIL) Commodity Forecast: Up 5.3% Today

Novavax Inc. ($NVAX) Stock Forecast: Down 7.6% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 6.1% Today

Ubiquiti ($UI) Stock Forecast: Down 6.8% Today

Corsair Gaming Inc. ($CRSR) Stock Forecast: Down 3.1% Today

Draftkings Inc ($DKNG) Stock Forecast: Up 5.2% Today

Chemours Company (The) ($CC) Stock Forecast: Down 5.2% Today

Teleflex Incorporated ($TFX) Stock Forecast: Up 7.9% Today

Fortinet Inc. ($FTNT) Stock Forecast: Up 20.9% Today

PTC Inc. ($PTC) Stock Forecast: Up 9.9% Today

Moderna Inc. Price History

07.04.2026 - MRNA Stock was up 8.5%

• The surge in Moderna's stock is likely linked to positive updates regarding its mRNA-1010 candidate for seasonal influenza, which displayed superior efficacy in Phase 3 trials compared to traditional flu vaccines.
• The announcement of the vaccine's robust relative efficacy, particularly in adults over 65 and overall, against different influenza strains, likely bolstered investor faith in Moderna's vaccine portfolio.
• The anticipation surrounding the potential FDA verdict on the vaccine by August 5, 2026, coupled with ongoing evaluations by regulatory bodies in various nations, contributed to the optimistic outlook on Moderna's influenza vaccine, fueling the stock's bullish movement.

06.04.2026 - MRNA Stock was up 5.3%

• Moderna (MRNA) stock showed a strong bullish trend today, despite posting a quarterly revenue of $389 million and a GAAP net loss of $1.34 billion, both higher than the previous year.
• The upturn in the stock could be due to an analyst reiterating a Buy rating on Moderna with a price target of $69.00, signaling optimism and growth potential for the company.
• Market participants may be hopeful about Moderna's future performance, given the advancements in the healthcare sector and the company's ongoing work in vaccine research and development.
• The positive market sentiment towards healthcare and the recommendation from the analyst likely contributed to the stock's bullish movement today.

29.03.2026 - MRNA Stock was down 5.1%

• Moderna's stock saw a decline after a revision of Q1 earnings estimates by an investment firm, resulting in a consensus full-year estimate in negative territory.
• Despite surpassing Q4 earnings estimates, Moderna experienced a 33.2% drop in revenue compared to the previous year, causing concerns among investors and contributing to the bearish trend.
• The pessimistic outlook on Moderna's earnings, in combination with overall market sentiment, likely triggered a sell-off as investors reassessed their stakes in the company.
• The decline in Moderna's stock price contrasts with positive developments in other biopharmaceutical companies, such as Regeneron and Biogen, which reported strong earnings and strategic acquisitions, respectively, showcasing the competitive nature of the biotech industry.

23.03.2026 - MRNA Stock was down 5.2%

• The decline in Moderna's stock value could be linked to a notable loss in U.S. government funding for its mRNA research. However, the company showed recovery as it began a Phase 3 trial for an mRNA bird flu vaccine.
• Despite the European Commission approving Moderna's COVID-19-influenza combination vaccine, it was not sufficient to counterbalance the impact of the funding loss from the U.S., prompting concerns among investors regarding the company's financial well-being.
• Investor focus on Regeneron Pharmaceuticals, reinforced by Cantor Fitzgerald's "Overweight" rating and strong quarterly EPS results, potentially diverted attention from Moderna, contributing to the downward trend in its stock performance.
• Additionally, the optimistic prospects for Thermo Fisher Scientific, driven by onshoring initiatives, may have attracted investor interest away from Moderna's ongoing challenges, further influencing its stock price.

01.04.2026 - MRNA Stock was down 5.1%

• Moderna posted robust Q1 revenue, fueled by strong international sales of COVID-19 vaccines, although it incurred a substantial net loss mainly attributed to a $950 million settlement for a patent dispute.
• Despite surpassing revenue projections and showcasing progress in its pipeline, the market responded negatively to the company's increased net loss and negative gross margins stemming from the litigation charge.
• Observers are closely monitoring Moderna's pipeline advancements, notably the forthcoming FDA verdict on the mRNA-1010 flu vaccine and advanced oncology trials, as these factors impact the stock's premium valuation despite uncertainties regarding profitability.
• Market sentiment towards Moderna appears to be swayed by the company's financial results, legal challenges, and the critical role of its pipeline in determining its future prospects.

01.04.2026 - MRNA Stock was down 5.2%

• Strong Q1 2026 financial results were reported by Moderna, with significant revenue growth driven by higher international sales of its COVID-19 vaccine. Despite this positive development, the stock witnessed a bearish movement, potentially linked to profit-taking after a period of strong performance.
• The company's GAAP net loss, attributed to a non-recurring litigation settlement charge, may have also contributed to investor concerns despite the revenue beat.
• Moderna's stock price surge in premarket trading and after-market hours suggests that investors initially reacted positively to the earnings report, but the bearish movement during the trading day indicates a shift in sentiment.
• The reaffirmed growth outlook and expansion into new product approvals demonstrate Moderna's commitment to innovation and long-term growth, which could potentially attract investors back to the stock in the future.

28.03.2026 - MRNA Stock was down 5.1%

• Concerns arose among investors regarding Moderna's collaboration with Salesforce to enhance its commercial operations, potentially leading to worries about integration challenges or operational disruptions.
• High expectations following the presentation of promising combination therapies at AACR 2026 may have disappointed investors if they perceived Moderna's current pipeline as less competitive for future cancer treatment developments.
• Speculation surrounding Moderna's upcoming Q1 2026 earnings report, particularly with projected losses per share, might have contributed to a negative investor sentiment prompting the stock's bearish trend.
• Attention on innovative therapies for diabetic retinopathy and Revolution Medicines' forthcoming annual meeting possibly overshadowed Moderna's core business, impacting investor confidence and attributing to the bearish stock movement.

24.03.2026 - MRNA Stock was down 6.6%

• Moderna (MRNA) recently saw a decrease in its stock price, potentially related to the upcoming financial report projecting an expected decrease in EPS and revenue, as well as ongoing financial difficulties and insider selling.
• This downward trend could be influenced by negative profit margins, projected annual losses, and challenges resulting from reductions in U.S. government funding for its bird-flu initiative.
• While the recent approval of mCOMBRIAX in the EU and ongoing Phase 3 trial for a bird-flu vaccine may have provided some positive momentum, concerns about the company's financial performance appear to have overshadowed these advancements in its product pipeline.
• Investors may be exercising caution due to conflicting signals regarding Moderna's financial prospects and the competitive environment within the biotechnology sector, illustrated by expansions in the CMV infection and iPSC-derived NK cells portfolios.

24.03.2026 - MRNA Stock was down 5.6%

• Expectations for Moderna's (MRNA) Q1 2026 earnings are pessimistic, with analysts predicting a loss. Ongoing financial difficulties, negative margins, and insider selling are among the factors contributing to the downward movement.
• While potential positives like EU approval for mCOMBRIAX and a Phase 3 bird-flu vaccine trial could provide a boost, past funding reductions for its bird-flu program in the U.S. are seen as challenges affecting investor confidence.
• The market's general sentiment towards biotech companies may also be influencing the bearish trend. This is exemplified by the contrasting performance of Regeneron Pharmaceuticals, which received a positive rating reassessment amid the sector's fluctuations.

30.03.2026 - MRNA Stock was up 5.2%

• Moderna experienced a notable bullish movement recently, potentially due to improved market sentiment after a period of losses. This rebound might signal restored investor faith in the company.
• Anticipation surrounding the upcoming earnings announcement on May 1, 2026, is likely fueling investor interest, leading to heightened purchasing activity and a rise in the stock's value.
• Positive analyses indicating long-term stock strength may be prompting traders to take positions, particularly given specified entry, target, and stop-loss levels for various trading strategies.
• Factors such as the resolution of a patent dispute with Roivant Sciences Ltd. and encouraging Phase 3 outcomes for Batoclimab may also be bolstering Moderna's resilience and growth prospects within the biopharmaceutical field.

07.04.2026 - MRNA Stock was down 6.1%

• The stock of Moderna faced a downward trend today despite the positive developments related to its mRNA technology and vaccine progress.
• Following the release of robust Q1 outcomes and promising data on its COVID vaccine, Novavax's stock saw a significant increase, potentially shifting investor focus away from Moderna.
• Concerns arose within the biotech sector after the Phase 3 trial failure of Lipocine's LPCN 1154 for postpartum depression, impacting Moderna's stock.
• Internal disagreements at the FDA, exemplified by Sanofi requesting the removal of Tzield from the CNPV program, might have instigated uncertainty over regulatory procedures for companies like Moderna, influencing the downward movement.

06.04.2026 - MRNA Stock was up 5.0%

• Moderna (MRNA) witnessed a notable surge in its stock price today, which could potentially be attributed to the following factors:
• A reiterated Buy rating by Piper Sandler analyst Edward Tenthoff with a price target of $69.00, reflecting confidence in the company's future prospects.
• Notwithstanding the disclosure of a quarterly revenue amounting to $389 million and a substantial GAAP net loss, the upbeat analyst sentiment and growth potential might have uplifted investor confidence.
• The prevailing positive sentiment towards biopharmaceutical firms in the market, apparent from the achievements and favorable developments of other companies like Edgewise Therapeutics and Cellectar Biosciences, could have also influenced Moderna's upward movement.
• Investors could be placing greater emphasis on the long-term promise of Moderna's mRNA technology and its pivotal role in shaping forthcoming vaccines and therapeutics, rather than solely focusing on near-term financial indicators.